J Clin Oncol: Fluorouracil/leucovorin combined with panitumumab maintenance therapy can significantly prolong the survival of patients with RAS wild-type metastatic colorectal cancer

Microsatellite stable metastatic colorectal cancer (mCRC) that has not been treated before is usually treated with a combination of fluorouracil and leucovorin (FU/FA) + oxaliplatin (FOLFOX) or (and) irinotecan
.
In addition, these chemotherapy regimens may also add monoclonal antibodies that target epidermal growth factor receptor (EGFR) or vascular endothelial growth factor

.

Colorectal cancer blood vessels

The PANAMA trial is a randomized controlled study designed to evaluate the effect of adding panitumumab (Pmab) to the maintenance treatment of fluorouracil and folinic acid in patients with RAS wild-type metastatic colorectal cancer
.

To evaluate the effect of adding panitumumab (Pmab) to the maintenance therapy of fluorouracil and leucovorin in patients with RAS wild-type metastatic colorectal cancer The effect of adding panitumumab (Pmab) to maintenance treatment

After 6 courses of FU/FA and oxaliplatin+Pmab first-line induction therapy, responders (stable disease or partial/complete remission) were randomized 1:1 to the FU/FA+Pamb maintenance treatment group or FU/FA Maintenance treatment group
.
The main purpose is to clarify the superiority of FU/FA+Pamb maintenance therapy in terms of progression-free survival (PFS, from randomization to disease progression or death)

.

PFS and OS of the two groups analyzed in total

PFS and OS of the two groups analyzed in total

In total, a total of 248 patients were randomly assigned to the FU/FA+Pamb group (n=125) or FU/FA group (n=123)
.
At the cut-off date, the PFS of FU/FA+Pamb maintenance treatment was significantly longer than that of FU/FA maintenance treatment (8.

8 vs 5.

The PFS of FU/FA+Pamb maintenance treatment was significantly longer than that of FU/FA maintenance treatment.

Partial adverse events

Partial adverse events

During maintenance treatment, the most common adverse event of grade 3 and above was skin rash (7.
2%)
.

In summary, for patients with RAS wild-type metastatic colorectal cancer, the use of FU/FA combined with Pmab maintenance therapy can induce a progression-free survival time that is significantly longer than that of FU/FA maintenance therapy
.
If the patient desires active maintenance therapy after FU/FA+oxaliplatin+Pmab induction therapy, FU/FA+Pmab may be the most advantageous choice

.

For patients with RAS wild-type metastatic colorectal cancer, the use of FU/FA combined with Pmab maintenance treatment can induce a progression-free survival time significantly longer than that of FU/FA maintenance treatment.

Original source:

Dominik Paul Modest, et al.

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212) in this message